This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
FELZARTAMAB en el Rechazo mediado por Anticuerpos - El Resumen Visual
El Resumen Visual
El Ferzartamab muestra resultados prometedores en el tratamiento del rechazo mediado por anticuerpos en trasplantados renales. En este ensayo clínico fase 2 aleatorizado, se evaluó el perfil de seguridad y los resultados secundarios a las 24 semanas.
¿Podría este anticuerpo anti-CD38 ser la nueva opción terapéutica revolucionaria para prevenir la pérdida del injerto mediada por anticuerpos? Observa el resumen visual realizado por el pasante del NSMC, Dr. Shahin Mohammed.
FELZARTAMAB in Antibody Mediated Rejection - The Visual Abstract
Can felzartamab represent a new hope for antibody-mediated rejection? Check out the visual abstract by Shahin Mohammed
🤔 Hypothermia or machine perfusion for kidney transplant?
Hypothermia or Machine Perfusion in Kidney Donors (Malinoski, NEJM 2023)
🤔 Precision diagnostics of kidney allograft biopsies
An automated histological classification system for precision diagnostics of kidney allografts (Yoo, Nature Medicine 2023)
The ENAKT-LKD Visual Abstract
Another sterlling visual abstract from Milagros Flores
Unlocking the door to living kidney donor paradise?
This week, nephrologists hope they found the key to no-dialysis-land, where kindness and detailed, multistep interventions make the path to kidney transplant much easier. This was foreseen in our Freely Filtered episode and disputed during #KidneyWK 2023 late-breaking clinical trials session. Still, when it comes to RCTs’ results, will it be Deja Vu or a happy ending?
The BEST-FLUID Visual Abstract
Is intravenous fluid therapy with a balanced crystalloid solution better than saline for patients receiving a deceased donor kidney transplant? Check out the BEST-FLUID VA by NSMC Intern Anitha Swami
